0002086827-25-000002.txt : 20250922 0002086827-25-000002.hdr.sgml : 20250922 20250922191818 ACCESSION NUMBER: 0002086827-25-000002 CONFORMED SUBMISSION TYPE: 144 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20250922 DATE AS OF CHANGE: 20250922 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 144 SEC ACT: 1933 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 251331303 BUSINESS ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 REPORTING-OWNER: COMPANY DATA: COMPANY CONFORMED NAME: Haque-Ahmed Rumana CENTRAL INDEX KEY: 0002086827 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 144 MAIL ADDRESS: STREET 1: C/O TAYSHA GENE THERAPIES, INC. STREET 2: 3000 PEGASUS PARK DRIVE, SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 144 1 primary_doc.xml 144 0002086827 XXXXXXXX LIVE 0001806310 TAYSHA GENE THERAPIES, INC. 001-39536 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 214-612-0000 Rumana Haque-Ahmed Officer Common Stock Maxim Group LLC

300 Park Avenue, 16th Floor New York NY 10022

10770 30479.1 272794885 09/22/2025 Nasdaq Common Stock 09/22/2025 RSU Award Issuer N 10770 09/22/2025 Vested grant settled instock; consideration was Reporting Person's continued service as an employee ofthe Issuer. Y The Reporting Person is selling the securities set forth herein pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only. 09/22/2025 /s/ Rumana Haque-Ahmed